STAAR Surgical stock faces a lower $23 price target

Published on 09/22/2026 at 19:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

STAAR Surgical stock faces a Jefferies target cut to $23 from $28 on September 22, 2026. The company also faces a $1.2 billion market value.

STAA, US8577001096, Illustration mit AI erstellt.

STAAR Surgical Company (US8577001096) faces a lower Jefferies price target of USD 23 from USD 28 on September 22, 2026, a USD 5 reduction that puts the analyst view at the center of the stock story. Bitget News reported the target change for STAAR Surgical.

Jefferies cuts target by USD 5

The revised USD 23 target compares with the previous USD 28 target, a decline of 17.9 percent. That quantified change is the clearest current analyst signal for STAA stock on September 22, 2026, although the available report does not state a new rating or provide a revised earnings forecast.

The target action matters because STAAR Surgical operates in a medical-device market where valuation depends on procedure growth, product adoption and expectations for future earnings. The USD 5 reduction therefore gives investors a concrete reference point for the current debate without establishing a new company forecast.

Market value remains near USD 1.2 billion

STAAR Surgical was reported at USD 24.43 per share with a market capitalization of USD 1.2 billion in a September 2026 market report. Ground News also described the stock as down 3.7 percent in that report.

The comparison between the USD 24.43 market price and the revised USD 23 target leaves a gap of USD 1.43, or 5.9 percent, using the reported figures. The same report identifies the market capitalization as USD 1.2 billion, making the target revision material for a company of this size.

STAA stock holds a defined reference point

For investors, the key reference points are now the USD 23 Jefferies target, the former USD 28 target and the reported USD 24.43 share price. Together, those figures show a lower analyst valuation marker alongside a market price that remained above the revised target in the cited September 2026 report.

STAAR Surgical Company is listed on Nasdaq under the ticker STAA. The company develops implantable ophthalmic lenses, so procedure volumes and demand for its products remain central operating factors, while the current evidence here is concentrated on valuation and market data.

STAAR Surgical stock trades at USD 24.43

STAAR Surgical stock was reported at USD 24.43 per share on Nasdaq in September 2026, alongside a 3.7 percent decline and a USD 1.2 billion market capitalization. The price, change and market value are the dated market figures available for the current stock context.